Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
The enterprise value (EV) is $276.76M.
ENTERPRISE VALUE (EV)
$276.76M
TriSalus Life Sciences, Inc.
Market Cap
$262.92M
Enterprise Value (EV)
$276.76M
| NAME | MARKET CAP | ENTERPRISE VALUE (EV) |
|---|---|---|
| TriSalus Life Sciences, Inc. (TLSI) | $262.92M | $276.76M |
| Scribe Therapeutics Inc. (SCTX)vs › | $264.25M | N/A |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $261.43M | $230.22M |
| X4 Pharmaceuticals, Inc. (XFOR)vs › | $261.27M | $143.39M |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $265.78M | $177.69M |
| OraSure Technologies, Inc. (OSUR)vs › | $259.56M | $111.07M |
| Treace Medical Concepts, Inc. (TMCI)vs › | $259.49M | $319.57M |
| SAB Biotherapeutics, Inc. (SABS)vs › | $266.59M | $263.46M |
| Eupraxia Pharmaceuticals Inc. (EPRX)vs › | $259.14M | $208.65M |
| Lexeo Therapeutics, Inc. Common Stock (LXEO)vs › | $259.12M | $173.10M |
Market Cap
$262.92M
Total Debt
$34.27M
Cash
$20.44M
Enterprise Value
$276.76M
Why use EV instead of Market Cap?
Enterprise Value represents the total value of a company as if you were to acquire it completely - paying for equity while assuming debt and receiving cash.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
